IMMUNOGENICITY AND PROTECTIVE EFFICACY OF ANTI-T. CRUZI NASAL VACCINE PROTOTYPES BASED ON TRANSIALIDASE

MARÍA FLORENCIA PACINI; FLORENCIA BELÉN GONZÁLEZ; SILVINA RAQUEL VILLAR; CECILIA FARRÉ; NICOLÁS JUAN CABRAL; ESDRAS DA SILVA BARBOSA OLIVEIRA ; GUSTAVO FRANCISCO CHAPO; GABRIEL CABRERA; IVÁN BONTEMPI; ESTEFANÍA PROCHETTO; MARTIN ESPARIZ; VICTOR BLANCATO; CHRISTIAN MAGNI; IVAN MARCIPAR; ANA ROSA PÉREZ

Congreso; SAI.SACI.SAFIS 2018; 2018

Sociedad Argentina de Inmunología

Currently there is not available a prophylactic vaccine for Chagasdisease. Therefore, in this work we evaluated whether the administrationof different nasal vaccine prototypes could prevent the developmentof T. cruzi (Tc) infection through the induction of specific andsystemic immune response. A fragment from the immunodominantparasite antigen called transialidase (TSf), containing both B andT epitopes was selected by bioinformatics. TSf was expressed ina L. lactis recombinant strain and then purified, avoiding the presenceof endotoxins like LPS in vaccine formulations. Thus, femaleBalb/c mice (n= 5-6/group) were immunized by intranasal route(three doses, one every two weeks) with different vaccine formulationscombining TSf with different adjuvants (c-di-AMP or ISPA).We also assayed the whole recombinant L. lactis expressing TSf asdelivery system plus c-di-AMP (LL-TSf+c-di-AMP). Non immunizedmice were used as control group (Co). In immunized mice, humoraland cellular immune responses were assayed prior to infection. Afteroral infection with 2500 Tc/mice (Tulahuen strain), the parasitemiaand the clinical score were determined. Intranasal immunized micewith TSf+c-di-AMP showed enhanced levels of IgG2a and IgG1compared to TSf and Co groups (in all cases, p